Chicago Partners Investment Group’s Vaxcyte PCVX Stock Holding History

Chicago Partners Investment Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,431	Closed	-$440K	–	981
2024 Q4	$440K	Buy	5,431 +458	+9%	+$45.5K	0.01%	543
2024 Q3	$558K	Sell	4,973 -93	-2%	-$8.38K	0.02%	460
2024 Q2	$405K	Sell	5,066 -943	-16%	-$64.2K	0.02%	523
2024 Q1	$366K	Buy	6,009 +132	+2%	+$9.14K	0.02%	520
2023 Q4	$372K	Sell	5,877 -1,285	-18%	-$66.7K	0.02%	492
2023 Q3	$336K	Buy	7,162 +1,005	+16%	+$49.6K	0.02%	488
2023 Q2	$309K	Sell	6,157 -1,002	-14%	-$47.5K	0.02%	523
2023 Q1	$311K	Buy	+7,159	New	+$304K	0.02%	500
2022 Q4	–	Sell	-6,402	Closed	-$278K	–	654
2022 Q3	$278K	Buy	+6,402	New	+$162K	0.02%	457
2021 Q1	–	Sell	-10,653	Closed	-$268K	–	531
2020 Q4	$268K	Buy	+10,653	New	+$396K	0.03%	386

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Chicago Partners Investment Group's PCVX Position: Q1 2025 in Review

Chicago Partners Investment Group sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 5,431 shares — an estimated $440K sold.

Chicago Partners Investment Group first reported a position in PCVX in Q4 2020 and held it in 10 quarters. The position peaked at $558K in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

Chicago Partners Investment Group reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
Chicago Partners Investment Group sold 5,431 Vaxcyte shares in Q1 2025, an estimated $440K.
Chicago Partners Investment Group first reported a position in Vaxcyte in Q4 2020 and held it in 10 quarters.
Chicago Partners Investment Group's Vaxcyte position peaked at $558K in Q3 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Chicago Partners Investment Group's 13F filing for Q1 2025, filed 9 May 2025.